Augmentation therapy in alpha-1 antitrypsin deficiency.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712598.8.4.515 PMID 18352854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z.

  2009cited by this paper
• Alpha One Antitrypsin Deficiency: From Gene to Treatment

  2007cited by this paper
• Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira.

  2006cited by this paper
• Alpha1-antitrypsin deficiency.

  2005cited by this paper
• Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk.

  2004cited by this paper
• Augmentation therapy for alpha(1)-antitrypsin deficiency.

  2004cited by this paper
• Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin.

  2004cited by this paper
• α1-Antitrypsin deficiency · 1: Epidemiology of α1-antitrypsin deficiency

  2004cited by this paper
• Role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency.

  2004cited by this paper
• American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

  2003cited by this paper
• Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.

  2003cited by this paper
• Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency.

  2003cited by this paper
• The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.

  2002cited by this paper
• Alpha1-antitrypsin: not just an antiprotease: extending the half-life of a natural anti-inflammatory molecule by conjugation with polyethylene glycol.

  2002cited by this paper
• Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.

  2002cited by this paper
• Acid Denaturation of alpha1-antitrypsin: characterization of a novel mechanism of serpin polymerization.

  2002cited by this paper
• Alpha1-antitrypsin deficiency--a model for conformational diseases.

  2002cited by this paper
• Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy.

  2002cited by this paper
• Alpha-1-Antitrypsin and a Broad Spectrum Metalloprotease Inhibitor, RS113456, Have Similar Acute Anti-Inflammatory Effects

  2001cited by this paper
• Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society.

  2001cited by this paper
• Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.

  2001cited by this paper
• Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group.

  2000cited by this paper
• Structure of a serpin–protease complex shows inhibition by deformation

  2000cited by this paper
• Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis.

  2000cited by this paper
• Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.

  2000cited by this paper
• Pathogenic α1-Antitrypsin Polymers Are Formed by Reactive Loop-β-Sheet A Linkage*

  2000cited by this paper
• A Kinetic Mechanism for the Polymerization of α1-Antitrypsin*

  1999cited by this paper
• A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.

  1999cited by this paper
• Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.

  1998cited by this paper
• Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group.

  1998cited by this paper
• Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency.

  1997cited by this paper
• Clinical features and natural history of severe alpha 1-antitrypsin deficiency. Roger S. Mitchell Lecture.

  1997cited by this paper
• Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.

  1997cited by this paper
• Structural insights into serpin—protease complexes reveal the inhibitory mechanism of serpins

  1997cited by this paper
• Inhibitory conformation of the reactive loop of alpha 1-antitrypsin.

  1996cited by this paper
• A 30-year perspective on alpha 1-antitrypsin deficiency.

  1996cited by this paper
• Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin-deficient humans.

  1995cited by this paper
• Secretion of alpha 1-antitrypsin by alveolar epithelial cells.

  1994cited by this paper
• The mechanism of Z alpha 1-antitrypsin accumulation in the liver.

  1992cited by this paper
• Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease.

  1991cited by this paper
• Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency.

  1988cited by this paper
• Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency.

  1988cited by this paper
• Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema.

  1987cited by this paper
• Expression of the alpha-1-antitrypsin gene in mononuclear phagocytes of normal and alpha-1-antitrypsin-deficient individuals.

  1986cited by this paper
• Preparation and Properties of Alpha1‐Proteinase Inhibitor Concentrate from Human Plasma

  1985cited by this paper
• Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema.

  1981cited by this paper
• Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects.

  1981cited by this paper
• Management of chronic obstructive pulmonary disease.

  1969cited by this paper

• Tumor necrosis factor-α driven inflammation in alpha-1 antitrypsin deficiency: a new model of pathogenesis and treatment

  2016cites this paper
• Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.

  2016cites this paper
• Single amino acid substitutions in recombinant plant-derived human α1-proteinase inhibitor confer enhanced stability and functional efficacy.

  2014cites this paper
• Expression and characterization of recombinant human alpha-antitrypsin in transgenic rice seed.

  2013cites this paper
• α-1 antitrypsin and chronic fatigue syndrome: a case study from pathophysiology to clinical practice.

  2013cites this paper
• Differential subcellular targeting of recombinant human α₁-proteinase inhibitor influences yield, biological activity and in planta stability of the protein in transgenic tomato plants.

  2012cites this paper
• The role of augmentation therapy in alpha-1 antitrypsin deficiency

  2011cites this paper
• Lung deposition of inhaled Alpha-1-proteinase inhibitor (Alpha1-PI) - problems and experience of Alpha1-PI inhalation therapy in patients with hereditary Alpha1-PI deficiency and cystic fibrosis

  2010cites this paper
• Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity.

  2010cites this paper
• Innovations in aortic disease: the ascending aorta and aortic arch.

  2010cites this paper
• Hypersensitivity Vasculitis with Leukocytoclastic Vasculitis Associated with Alpha-1-Proteinase Inhibitor

  2010cites this paper
• Alpha1-antitrypsin deficiency: forgotten etiology.

  2010cites this paper
• Intravenous alpha-1 antitrypsin augmentation therapy: systematic review.

  2010cites this paper
• Serine proteases of the human immune system in health and disease.

  2010cites this paper
• Expression and purification of recombinant human alpha1-proteinase inhibitor and its single amino acid substituted variants in Escherichia coli for enhanced stability and biological activity.

  2010cites this paper
• Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.

  2010cites this paper
• Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy

  2009cites this paper
• High-level expression of active human alpha1-antitrypsin in transgenic tobacco chloroplasts

  2009cites this paper
• Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options?

  2009cites this paper
• α1-Antitrypsin deficiency: best clinical practice

  2009cites this paper